AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, ...

AbbVie and RemeGen have signed the first deal of the J.P Morgan Healthcare Conference 2026, with the companies agreeing to an exclusive oncology licensing agreement. The oncology-focused deal – which ...

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ ...

Immunology is AbbVie's primary core competency. While the pharmaceutical company has successfully transitioned patients from Humira to its newer blockbusters, Skyrizi and Rinvoq, the Apogee ...

It is certainly a good Dividend King to buy in September.

ADARx Pharmaceuticals’ IPO aims to fund its RNA therapy pipeline; see Phase 3 Onvuzosiran timeline and AbbVie deal validation ...

Here's a list of key deals reported across sectors this week: ...

On April 27, 2026, AbbVie announced that it has submitted a regulatory application to the FDA seeking approval for SKYRIZI (risankizumab-rzaa) for subcutaneous induction for the treatment of adult ...

AbbVie's dividend is a very appealing factor.

AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price ...